行情

GLMD

GLMD

Galmed制药
NASDAQ

实时行情|Nasdaq Last Sale

4.660
+0.050
+1.08%
已收盘, 16:00 08/07 EDT
开盘
4.570
昨收
4.610
最高
4.690
最低
4.480
成交量
5.34万
成交额
--
52周最高
7.38
52周最低
3.020
市值
9,838.69万
市盈率(TTM)
-4.2756
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GLMD价格均价为19.86,最高价位33.00,最低价为8.00。

EPS

GLMD 新闻

更多
Galmed EPS beats by $0.06
Galmed (NASDAQ:GLMD): Q2 GAAP EPS of -$0.26 beats by $0.06. As of June 30, 2020, cash and equivalents of $5.55M vs. $15.93M as of December 31, 2019. Press
seekingalpha · 3天前
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or
PR Newswire · 3天前
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.
PR Newswire · 3天前
Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the treatment of nonalc
PR Newswire · 07/30 12:30
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential
On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that
TipRanks · 07/14 21:31
IPO Update: Inventiva SA Looks For $102 Million U.S. IPO
Seeking Alpha - Article · 07/06 21:58
Here is What Hedge Funds Think About Galmed Pharmaceuticals Ltd (GLMD)
Insider Monkey · 07/06 12:55

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

GLMD 简况

Galmed Pharmaceuticals Ltd.是一家临床阶段的生物制药公司。该公司专注于利用合成的aramchol脂肪酸/胆汁酸缀合物(FABAC)开发和销售用于治疗肝脏疾病和胆固醇结石的每日一次口服治疗产品。其候选产品aramchol是一种脂肪肝疾病(包括非酒精性肝炎(NASH))的疾病改善治疗产品。该公司的Aramchol是胆酸和花生酸的缀合物,是合成脂肪酸/胆汁酸缀合物(FABAC)的组份。FABAC由内源性化合物组成。阿胺酚影响肝脏脂肪代谢,已于IIa期临床研究中证明能降低肝脏脂肪含量,并改善与非酒精性脂肪性肝炎(NASH)相关的代谢参数。Aramchol正处于IIb期临床试验阶段。
展开

微牛提供Galmed Pharmaceuticals Ltd(NASDAQ-GLMD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GLMD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GLMD股票基本功能。